© Reuters. BioNTech (BNTX) Stocks Pops on Big Sales Beat
Shares of BioNTech (NASDAQ:) are up around 1.5% in pre-open Monday after the biotech company reported better-than-expected Q1 EPS and revenue.
The German biotechnology company a Q1 EPS of €14.24, up from €4.39 in the year-ago period and the consensus estimates of €8.62. Revenue came in at €6.37, topping the estimated €4.01 billion.
In the first quarter, BioNTech generated €1.16 billion in direct coronavirus vaccine sales in Germany and Turkey, in addition to €603.2 million in sales of products made by BioNTech for its partners.
Commercial revenues in the first quarter included €4.59 billion gross profit share in territories allocated between Pfizer (NYSE:), BioNTech, and Fosun Pharma (SS:) (HK:).
For the full fiscal year, BNTX expects capital expenditure in the range of €450 million to €550 million, while analysts were looking for €390.3 million. Coronavirus vaccine revenue is expected to be in the range of €13 billion to €17 billion, compared to the consensus projection of €15.62 billion.
By Senad Karaahmetovic
Be the first to comment